ChemicalBook > CAS DataBase List > Febuxostat

Febuxostat

Product Name
Febuxostat
CAS No.
144060-53-7
Chemical Name
Febuxostat
Synonyms
FBX;Uloric;Febuxostat Impurity;2-(3-cyano-4-isobutoxyphenyl);TMX 67;CS-1598;Tei-6720;NSC63871;Febrista;Adenuric
CBNumber
CB4841564
Molecular Formula
C16H16N2O3S
Formula Weight
316.37
MOL File
144060-53-7.mol
More
Less

Febuxostat Property

Melting point:
238-239°(dec.)
Boiling point:
536.6±60.0 °C(Predicted)
Density 
1.31±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
2.48±0.10(Predicted)
form 
powder
color 
White to Off-White
Merck 
14,3948
InChI
InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)
InChIKey
BQSJTQLCZDPROO-UHFFFAOYSA-N
SMILES
S1C(C(O)=O)=C(C)N=C1C1=CC=C(OCC(C)C)C(C#N)=C1
CAS DataBase Reference
144060-53-7(CAS DataBase Reference)
More
Less

Safety

RTECS 
XJ3675310
HS Code 
2934.10.2000
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML1285
Product name
Febuxostat
Purity
98.5-102.0% (HPLC)
Packaging
1G
Price
$213
Updated
2025/07/31
TCI Chemical
Product number
F0847
Product name
Febuxostat
Purity
>97.0%(HPLC)(T)
Packaging
1g
Price
$98
Updated
2025/07/31
TCI Chemical
Product number
F0847
Product name
Febuxostat
Purity
>97.0%(HPLC)(T)
Packaging
5g
Price
$316
Updated
2025/07/31
Cayman Chemical
Product number
14127
Product name
Febuxostat
Purity
≥98%
Packaging
5mg
Price
$57
Updated
2024/03/01
Cayman Chemical
Product number
14127
Product name
Febuxostat
Purity
≥98%
Packaging
10mg
Price
$107
Updated
2024/03/01
More
Less

Febuxostat Chemical Properties,Usage,Production

Description

Febuxostat, a selective xanthine oxidase inhibitor, was launched for the chronic management of hyperuricemia in patients with gout. Hyperuricemia is defined as a serum uric acid concentration exceeding the limit of solubility. It predisposes affected persons to gout, a disease characterized by the formation of crystals of monosodium urate or uric acid from supersaturated fluids in joints and other tissues. Crystal deposition is asymptomatic, but it is revealed by bouts of joint inflammation. If left untreated, further crystals accumulate in joints and can form deposits known as tophi. A major aim in gout management is the long-term reduction of serum uric acid concentrations below saturation levels, as this results in crystal dissolution and eventual disappearance.
Febuxostat is a nonpurine derivative with higher potency and selectivity than allopurinol for inhibiting xanthine oxidase. It completely inhibits human xanthine oxidase activity in the lung cancer cell line A549, whereas the activities of other enzymes involved in purine or pyrimidine metabolism (e.g., purine nucleoside phosphorylase, adenosine deaminase, and pyrimidine nucleoside phosphorylase) are affected by<4%.

Chemical Properties

Crystalline Solid

Physical properties

Febuxostat has low solubility. It is almost insoluble in acidic conditions, slightly soluble in neutral conditions, and slightly more soluble in alkaline conditions. It is not suitable for making injections, but it can be taken orally because of its high oil-water partition coefficient and strong ability to cross cell membranes.

Originator

Teijin (Japan)

Uses

Febuxostat is a new generation xanthine oxidase inhibitor developed by Tejin Co. (Japan,) used clinically for for long-term treatment of hyperuicemia (gout,) a new and highly effective non-purine selective inhibitor of xanthine oxidase. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout. It is not recommended for gout patients without hyperuricemia.

Preparation

Febuxostat can be synthesized in a multistep sequence from 2,4-dicyanophenol, starting with the alkylation of the phenolic hydroxyl group with isobutyl bromide and potassium carbonate, followed by treatment with thioacetamide in hot dimethyl formamide to yield 3-cyano-4-isobutoxythiobenzamide. Cyclization of the thioamide group with 2-chloroacetoacetic acid ethyl ester in refluxing ethanol affords 2-(3-cyano-4-isoutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, which is hydrolyzed with sodium hydroxide to produce febuxostat.

Definition

ChEBI: Febuxostat is a 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout. It has a role as an EC 1.17.3.2 (xanthine oxidase) inhibitor. It is an aromatic ether, a nitrile and a 1,3-thiazolemonocarboxylic acid.

brand name

Uloric, Adenuric

General Description

Febuxostat is a potent, non-purine compound, which inhibits the expression of cytokines/chemokines. It has also been reported to inhibit LPS-induced TNF-α, VCAM-1, MMP9 and MCP-1 expression.

Biological Activity

Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase. It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively). It is 10-30 times more potent than the hypoxanthine analog allopurinol (; Kis = 0.7 nM and 0.7 μM, respectively). Febuxostat decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg). It reduces hepatic macrovesicular steatosis in mice fed a high-fat diet containing trans fatty acids when administered at a dose of 1 mg/kg per day. Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE). Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.

Biochem/physiol Actions

Febuxostat is a potent non-purine xanithine oxidase inhibitor. Febuxostat is used in urate lowering therapies (ULTs) for the treatment of gout.

Clinical Use

Fabuxostat was discovered by Teijin Pharmaceuticals and licensed to TAP Pharmaceuticals (which is currently part of Takeda Pharmaceuticals) and was approved in the U.S. for the treatment of hyperuricemia in patients with gout. It is a once-daily non-purine based agent with potent inhibitory activity against xanthine oxidase. The safety profile of the drug also does not require dose adjustment for patients with mild to moderate renal or hepatic impairment. Febuxostat is the first new agent cleared for this indication in 40 years.

Side effects

The incidence of adverse events such as dizziness, diarrhea, headache, and nausea with febuxostat was similar to allopurinol. Febuxostat is contraindicated in patients being treated with the xanthine oxidase substrates such as azathioprine, mercaptopurine, and theophylline.

Synthesis

There are a number of routes available to prepare this agent as discussed in recent publications. The synthesis shown in Scheme 10 is a short and concise route and does not require the use of toxic reagents. Thus the commercially available and easily prepared 4-hydroxythiobenzamide (52) was reacted with ethyl bromoacetoacetate (53) in refluxing ethanol to provide the thiazole ester 54 in ??60% yield after crystallization. The phenolic ester 54 was then treated with hexamethylenetetramine (HMTA) in polyphosphoric acid at 80 ??C to provide the crude aldehyde 55 (74% conversion by HPLC). Reaction of phenol 55 and isobutyl bromide (56) in the presence of potassium carbonate with catalytic potassium iodide in DMF gave isobutyl ether 57 (64%, two steps). This ether was then converted in one pot to nitrile 58 in 93% by reacting the aldehyde with hydroxylamine hydrochloride and sodium formate in refluxing formic acid. Saponification of the ester 58 with aqueous sodium hydroxide provided fabuxostat (X).

Drug interactions

Potentially hazardous interactions with other drugs
Azathioprine: avoid concomitant use, increased risk of neutropenia.
Cytotoxics: avoid concomitant use with mercaptopurine.
Theophylline: use with caution

Metabolism

Extensively metabolised by conjugation via the uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system, and by oxidation via the cytochrome P450 isoenzyme system to form active metabolites. About 49% of a dose is excreted via the urine, and 45% via the faeces (12% as unchanged drug)

storage

Store at RT

Mode of action

Xanthine oxidase is the main enzyme promoting uric acid production. It works by non-competitively blocking the molybdenum pterin center, which is the active site of xanthine oxidase. Through highly selective inhibition of oxidized and reduced xanthine oxidase, Febuxostat can reduce the synthesis of uric acid, decreasing its concentration and effectively treating gout. Through liver metabolism, Xanthine oxidase does not rely on renal excretion, so patients with moderate to severe liver and kidney dysfunction do not need to reduce dosages. Febuxostat is a non-purine XOR inhibitor, so it is very safe.

Febuxostat Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Febuxostat Suppliers

Americas 1 Argentina 2 Brazil 1 Canada 4 China 671 Cyprus 1 Europe 1 France 1 Germany 5 Greece 1 India 179 Indonesia 1 Israel 2 Italy 1 Japan 3 Mexico 1 Nepal 1 Philippines 1 South Korea 5 Spain 2 Switzerland 1 The Netherlands 2 United Arab Emirates 1 United Kingdom 12 United States 51 Global 951
Jai Radhe Sales
Tel
+(91)-(79)-26431096/65255722
Fax
+(91)-(79)-26569884
Email
info@jairadhesales.com
Country
India
ProdList
397
Advantage
60
GLR Innovations
Tel
+91 9891111994
Email
info@glrgroup.in
Country
India
ProdList
4535
Advantage
58
TCI Chemicals (India) Pvt. Ltd.
Tel
--
Fax
--
Email
sales-in@tcichemicals.com
Country
India
ProdList
6768
Advantage
58
VASUDHA PHARMA CHEM LIMITED
Tel
--
Fax
--
Email
vasudha@vasudhapharma.com
Country
India
ProdList
76
Advantage
58
ZYDUS LIFESCIENCES LTD
Tel
--
Fax
--
Email
investor.grievance@zyduscadila.com
Country
India
ProdList
68
Advantage
58
JUBILANT PHARMOVA LTD
Tel
--
Fax
--
Email
support@jubl.com
Country
India
ProdList
60
Advantage
58
Sun Pharmaceutical Industries Ltd.
Tel
--
Fax
--
Email
SunPharma.IndiaBusiness@sunpharma.com
Country
India
ProdList
99
Advantage
58
Progress Life Sciences Pvt. Ltd.
Tel
--
Fax
--
Email
info@progresslifesciences.com
Country
India
ProdList
25
Advantage
58
Saurav Chemicals Ltd.
Tel
--
Fax
--
Country
India
ProdList
9
Advantage
58
Globofarm International Private Limited
Tel
--
Fax
--
Email
procurement@globofarm.net
Country
India
ProdList
188
Advantage
58
MYLAN LABORATORIES LIMITED
Tel
--
Fax
--
Email
communications.inem@mylan.com
Country
India
ProdList
68
Advantage
58
Ayon PharmaChem
Tel
--
Fax
--
Email
bhargav@ayonpharmachem.com
Country
India
ProdList
303
Advantage
58
Corey Organics Private Ltd.
Tel
--
Fax
--
Email
nfo@coreyorganics.com
Country
India
ProdList
210
Advantage
58
Bioaltus
Tel
--
Fax
--
Email
info@bioaltus.com
Country
India
ProdList
10
Advantage
58
Monarch Pharmachem
Tel
--
Fax
--
Email
info@monarchpharmachem.com
Country
India
ProdList
52
Advantage
58
Zydus Cadila (Cadila Healthcare Ltd.)
Tel
--
Fax
--
Country
India
ProdList
33
Advantage
58
Imex Overseas
Tel
--
Fax
--
Email
info@imexoverseas.in
Country
India
ProdList
45
Advantage
58
Sign Pharma Trade Services Pvt., Ltd.(SPTS)
Tel
--
Fax
--
Email
info@signpharma.com
Country
India
ProdList
160
Advantage
58
MSN Laboratories Pvt., Ltd.
Tel
--
Fax
--
Email
api@msnlabs.com
Country
India
ProdList
38
Advantage
58
HRV Global Life Sciences Private Limited
Tel
--
Fax
--
Email
info@hrvglobal.com
Country
India
ProdList
190
Advantage
58
Apotex Pharmachem India Pvt., Ltd.
Tel
--
Fax
--
Email
mktgapipl@apotex.co.in
Country
India
ProdList
60
Advantage
58
Indexim International
Tel
--
Fax
--
Country
India
ProdList
112
Advantage
58
Placid Pharmachem
Tel
--
Fax
--
Email
parikshitjain@vsnl.com
Country
India
ProdList
115
Advantage
58
KPS Chemicals & Pharmaceuticals
Tel
--
Fax
--
Email
kpschempharma@gmail.com
Country
India
ProdList
240
Advantage
58
Excel Industries Limited
Tel
--
Fax
--
Country
India
ProdList
18
Advantage
58
Sudarshan Group
Tel
--
Fax
--
Email
vijaya@sudarshangrp.com
Country
India
ProdList
40
Advantage
58
Aril Pharmaceuticals (Aril Biosciences Pvt. Ltd.)
Tel
--
Fax
--
Email
marketing@arilpharmaceuticals.com
Country
India
ProdList
67
Advantage
58
Clearsynth Labs
Tel
--
Fax
--
Email
fo@clearsynth.com
Country
India
ProdList
3887
Advantage
58
Pure Chem Pvt., Ltd.
Tel
--
Fax
--
Email
info@purechemindia.com
Country
India
ProdList
10
Advantage
58
Neuland Laboratories Limited
Tel
--
Fax
--
Country
India
ProdList
10
Advantage
58
Yasham Speciality ingredients Pvt Ltd
Tel
--
Fax
--
Email
yasham@yasham.in
Country
India
ProdList
42
Advantage
58
Unimark Remedies Ltd.
Tel
--
Fax
--
Email
sapnasingh@unimarkremedies.com
Country
India
ProdList
26
Advantage
58
Eppion Lifesciences
Tel
--
Fax
--
Email
contact@eppionlifesciences.in
Country
India
ProdList
103
Advantage
58
Dharmanandan Export Pvt., Ltd.
Tel
--
Fax
--
Email
info@dnexport.com
Country
India
ProdList
161
Advantage
58
Gemini Exports
Tel
--
Fax
--
Email
uiry@geminiexpor
Country
India
ProdList
140
Advantage
58
METROCHEM API PRIVATE LTD
Tel
--
Fax
--
Email
contact@metroapi.com
Country
India
ProdList
41
Advantage
58
Shruti Drugs Pvt., Ltd.
Tel
--
Fax
--
Email
exports@shrutidrugs.com
Country
India
ProdList
13
Advantage
58
Kshatriya Laboratories Pvt. Ltd.
Tel
--
Fax
--
Email
info@kshatriyalabs.com
Country
India
ProdList
21
Advantage
58
Pharma Links
Tel
--
Fax
--
Email
info@pharmalinksindia.com
Country
India
ProdList
85
Advantage
58
Zydus Takeda Healthcare Pvt. Ltd.
Tel
--
Fax
--
Country
India
ProdList
6
Advantage
58
NIFTY LABS PVT. LTD
Tel
--
Fax
--
Email
info@niftylabs.com
Country
India
ProdList
38
Advantage
58
Indoco Remedies Ltd.
Tel
--
Fax
--
Email
corpcom@indoco.com
Country
India
ProdList
16
Advantage
58
Rivashaa Agrotech Biopharma Pvt. Ltd.
Tel
--
Fax
--
Email
source@rivashaa.com
Country
India
ProdList
986
Advantage
58
Goalsy Laboratories
Tel
--
Fax
--
Email
info@goalsylaboratories.com
Country
India
ProdList
42
Advantage
58
Athos Chemicals
Tel
--
Fax
--
Email
export@athoschemicals.com
Country
India
ProdList
315
Advantage
58
Dr. Reddys Laboratories Ltd.
Tel
--
Fax
--
Email
rashish@drreddys.com
Country
India
ProdList
59
Advantage
58
Synthink Research Chemicals
Tel
--
Fax
--
Country
India
ProdList
398
Advantage
58
Prudence Pharma Chem
Tel
--
Fax
--
Country
India
ProdList
11
Advantage
58
Radhashok Pharmachem Pvt., Ltd.
Tel
--
Fax
--
Email
priyanka@radhashok.com
Country
India
ProdList
30
Advantage
58
Hetero Drugs Limited
Tel
--
Fax
--
Country
India
ProdList
174
Advantage
58
More
Less

View Lastest Price from Febuxostat manufacturers

Jinan Ruitong Biotech Co., Ltd.
Product
Febuxostat 144060-53-7
Price
US $0.00-0.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
1
Release date
2025-08-21
Handan City Zechi trading Co., LTD
Product
Febuxostat 144060-53-7
Price
US $1.00/g
Min. Order
100g
Purity
99
Supply Ability
10000
Release date
2025-08-11
Shaanxi Dideu New Materials Co. Ltd
Product
Febuxostat 144060-53-7
Price
US $0.00/kg
Min. Order
1kg
Purity
98%
Supply Ability
1000kg
Release date
2025-06-29

144060-53-7, FebuxostatRelated Search:

Methylchloroisothiazolinone/methylisothiazolinone mixture (MCIT/MIT) Methyl salicylate Lithium tri-tert-butoxyaluminum hydride Ethyl cyanoformate Methyl 4-cyanobenzoate Tribenuron methyl 4-Biphenylcarboxylic acid Thiazole Methylene dithiocyanate Benzothiazole ethyl 2-(4-hydroxyphenyl)-4-methyl thiazole-5-carboxylate ETHYL 2-(3-FORMYL-4-ISOBUTOXYPHENYL)-4-METHYLTHIAZOLE-5-CARBOXYLATE Ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate 2-[2-(2-AMINO-9H-PURIN-9-YL)ETHYL]-1,3-PROPANEDIOL MONO-DESACETYL FAMCICLOVIR 4-HYDROXYTHIOBENZAMIDE Thiophanate-methyl THIAZOLE ORANGE

  • Febuxostat (Uloric)
  • FBX
  • Uloric
  • Febuxostat (TEI-6720)
  • Febuxostat Tablets
  • FEBUXOSTAT API
  • Febuxostat (This product is unavailable in the U.S.)
  • Febuxostat Tabletshehe
  • Febuxostat 2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid
  • Febuxostat, >=99%
  • Febuxostat Impurity
  • CS-1598
  • TEI 6720 - Febuxostat
  • 2-(3-cyano-4-isobutoxyphenyl)
  • Febuxostat IMP
  • Tei-6720
  • 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
  • 2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid
  • 2-(3-Cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic Acid
  • 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic Acid
  • TMX 67
  • FEBUXOSTAT
  • Febuxosta
  • Febuxostat Impurity V
  • Febuxostat(ThisproductisunavailableintheU.S.)&gt
  • 5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-
  • Febuxostat A
  • Fubuxostat
  • 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylicaci
  • Febuxostat USP/EP/BP
  • Febuxostat Working std
  • Febuxostat (A/C crystal)
  • FebuxostatQ: What is Febuxostat Q: What is the CAS Number of Febuxostat Q: What is the storage condition of Febuxostat Q: What are the applications of Febuxostat
  • NSC 63871
  • NSC63871
  • NSC-63871
  • The cloth sutent
  • Febrista
  • Fesotan *
  • Febuxostat（ China GMP ）
  • 2-(3-Cyano-4-isobutoxyphenyl)-4-methylthiazol-5-carboxylic acid
  • Febuxostat CRS
  • Febuxostat 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5- carboxylic acid
  • Febuxostat Form-A, C & G
  • Adenuric
  • Febuxostat Reference Standard
  • Febuxostat, 10 mM in DMSO
  • FEBUXOSTAT NON-STERILE BULK DRUG SUBSTANCE
  • Febuxostat - Bio-X ?
  • Febuxostat RS
  • 144060-53-7
  • Heterocycles
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • eterocycles
  • TRILIPIX
  • Other APIs